Galmed Pharmaceuticals develops therapeutics for liver diseases. Aramchol, their main product, is in Phase III study for NASH treatment. It also evaluates Aramchol through ARRIVE Study for HIV-associated non-alcoholic fatty liver disease. Additionally, they develop Amilo-5MER and MyBiotics, both in pre-clinical trials. They have agreements with Samil Pharma for commercialization in Korea and OnKai for AI platform collaboration. Founded in 2000, headquartered in Israel.
| Indicator | Value |
|---|---|
| PER | 48.6 |
| EV/EBITDA | - |
| Price/Free Cash Flow' | 45.3 |
| ROIC | -% |
| Net Debt/EBITDA | - |